Efficacy of a Simplified Diagnostic-Therapeutic Strategy Based on the Prostate-Pelvic Syndrome Theory Versus NIH Conventional Classification‑Based Protocol for Type III Prostatitis: A Randomized Controlled Trial.
Xiaoma Zhang, Li Xiao, Lei Zhou et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective randomized controlled trial compared a simplified prostate-pelvic syndrome (PPS)-guided individualized treatment strategy with a conventional NIH classification-based protocol in men aged 18–39 years with type III prostatitis. Of 222 randomized participants, 212 completed six weeks of treatment. The PPS group had a higher response rate, defined as a decrease of at least 6 points in NIH-CPSI total score, than the NIH group (79.6% versus 61.5%, p = 0.004). Greater improvement was mainly in the quality-of-life domain; pain and voiding changes did not differ significantly.
Key findings
- Response rates were 79.6% with PPS-guided treatment and 61.5% with the NIH protocol (p = 0.004).
- The median NIH-CPSI total-score decrease was greater in the PPS group (p = 0.003).
- Between-group improvement was driven mainly by quality of life (p = 0.003); pain and voiding changes did not differ significantly.
- PPS-based treatment independently predicted response (OR = 2.227, 95% CI: 1.143-4.337).
Why it matters
The trial suggests that an individualized, symptom-directed approach may improve overall symptom response in younger men with type III prostatitis compared with a conventional classification-based protocol. The quality-of-life contribution is clinically relevant because symptom burden extends beyond pain and urinary symptoms. However, the results do not establish which elements of the PPS pathway or treatment package account for the observed difference.
What to keep in mind
Follow-up was limited to six weeks, and the study authors state that the contribution of the simplified diagnostic pathway itself requires further study.